Calumet (NASDAQ:CLMT) Surprises With Strong Q2 CY2026

Calumet (NASDAQ:CLMT) reported Q2 CY2026 results. Revenue rose 40.8% year on year to $1.45 billion, beating Wall Street estimates by 32% (according to the article). Adjusted EBITDA exceeded consensus by 78.2%, with margin rising to 12.1%. Free cash flow was $99.35 million, turning positive after a year-ago loss.

Original reporting
Published Aug 7, 2026, 12:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 12:41 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Calumet (NASDAQ:CLMT) Surprises With Strong Q2 CY2026 — source image
Decision brief

The 30-second read

$CLMTBullishMed
01

Why it matters

The immediate trading relevance is the earnings surprise (revenue and adjusted EBITDA beats) and the margin expansion, while the longer-term risk is cash generation sensitivity to crude prices and prior cash burn.

02

Market read

A company-specific earnings beat can drive short-term repricing, but the article’s emphasis on cash-flow volatility suggests traders should watch for confirmation beyond EBITDA.

03

What to watch

The article notes elevated free-cash-flow volatility versus WTI (14.4) and negative average free-cash-flow margin over five years, which can dominate valuation even after an earnings beat.

Relevance 7/10Novelty 6/10Timing: reported Q2 CY2026 results today, with stock noted flat at $42.18 immediately after

Background

Calumet is a specialty products refiner, and the piece frames its Q2 performance using revenue growth, adjusted EBITDA margins, and free cash flow quality.

Company-level read

Ticker impact

$CLMTBullishMedium confidence
Context

Calumet reported Q2 CY2026 revenue up 40.8% to $1.45B and an adjusted EBITDA beat versus consensus, signaling stronger operating leverage.

Expected impact

Near-term upside bias versus expectations, with follow-through dependent on whether cash generation stabilizes.

Evidence & confidence

The article provides concrete earnings metrics (revenue, adjusted EBITDA, margins) and also flags cash burn history and higher sensitivity to WTI, which can cap the rally.

Market effects

Highlights that specialty refiners can show operating leverage in favorable commodity conditions, but cash-flow quality may diverge from EBITDA.

No specific regional demand or policy drivers cited.

No direct global macro or cross-border transaction details provided.

Counterpoint

The EBITDA beat may not translate into durable shareholder value if free cash flow stays negative and remains highly sensitive to WTI swings.

Key entities

  • Calumet

    Reported Q2 CY2026 revenue growth and adjusted EBITDA above consensus, with free cash flow turning positive after a year-ago negative quarter.

Related articles

$CLMTMed

S&P upgrades Calumet rating to B- on stronger earnings

S&P Global Ratings upgraded Calumet Inc. to 'B-' from 'CCC+' due to stronger earnings in H1 2026 and improved credit metrics. The company's earnings grew on high margins for specialty oils and renewable fuels. S&P expects adjusted debt to EBITDA of 6x-7x in the next 12 months. Calumet redeemed $100M in senior unsecured notes in July 2026 and plans to expand sustainable aviation fuel production.

$CLMTMedAI 8/10

Calumet (CLMT) Q2 2026 Earnings Call Transcript

Calumet (CLMT) reported Q2 2026 Adjusted EBITDA with Tax Attributes of $175.2 million, driven by Specialty Products and Solutions at $161.7 million. Net loss was $95.9 million, mainly from non-cash RINs expenses of $163.6 million. The company said it repaid $115 million of debt in July, including $100 million note redemption, and discussed SAF expansion and hedges.

$CLMTMed

Why Calumet Stock Is Rocketing Higher Today

Calumet (CLMT) shares rose 15.2% to about $5.99 by 2:36 p.m. ET after a 6.8% drop the prior week. Bank of America kept a buy rating and raised its price target to $45 from $38, citing stronger free cash flow and debt retirement. Calumet reported about $54M free cash flow in Q2 2026 and retired $115M debt in July.

$CLMTMedAI 8/10

CLMT Stock Jumps As Revenue Beats And Debt Falls

Calumet Inc (NASDAQ: CLMT) shares rose about 10.56% after Q2 results and guidance. The company reported Q2 revenue of $1.45B versus a FactSet estimate of $1.12B, with EPS improving to -$1.09 from -$1.70. Operating cash flow was about $92.3M and free cash flow about $54M, alongside $115M debt reduction in July. Goldman Sachs raised its CLMT price target to $40 from $36 but kept a Neutral rating.

$CLMTMed

CLMT Stock Jumps As Revenue Beat Fuels Deleveraging Story

Calumet Inc. (CLMT) shares rose about 10.56% after the company reported Q2 revenue of $1.45B versus $1.12B expected, and narrowed its EPS loss to -$1.09 from -$1.70. The quarter included $54M free cash flow and management cited $115M debt reduction in July, alongside a MaxSAF 150 expansion at Montana Renewables.

$CLMTMed

Why Calumet Stock Flopped on Friday

Calumet (CLMT) shares fell about 6% on Friday after its Q2 earnings showed a surprise net loss. Revenue rose to just under $1.45B, up about 41% YoY, but adjusted net loss was $95.9M, or $1.09/share, versus a year-ago deficit of $147.9M. Analysts expected profit of $0.17/share. Long-term debt exceeded $2.2B.